Eli Lilly to Acquire Sigilon Therapeutics
29 6월 2023 - 8:35PM
Dow Jones News
By Ben Glickman
Eli Lilly said Thursday it would acquire Sigilon Therapeutics in
a cash deal with additional contingent value rights.
The pharmaceutical company said it expected the deal to acquire
Sigilon for $14.92 per share in cash to close in the third quarter
of 2023. In the deal, shareholders of Sigilon may also receive up
to $111.64 per share in cash if certain conditions are met, such as
the use of Sigilon treatments in human subjects and the receival of
regulatory approvals.
The deal is worth a total of up to $309.6 million, excluding
shares of Sigilon currently held by Lilly.
Sigilon shares more than quadrupled in pre-market trading
Thursday after the announcement. The stock rose 369% to $18.31,
after falling 0.8% in Wednesday trading. Shares are still down 12%
year to date.
Lilly said the two companies had collaborated since 2018 to
develop encapsulated cell therapies, including SIG-002 to treat
type 1 diabetes.
The companies said the Sigilon board unanimously recommended
shareholders tender their shares.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 29, 2023 07:20 ET (11:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sigilon Therapeutics (NASDAQ:SGTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sigilon Therapeutics (NASDAQ:SGTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
